STARD3 and coronary artery disorder: The most significant association with TC and LDL-C reduction during 6 months of rosuvastatin therapy was found for SNP rs55730499 in LPA, whereas the rs881844 polymorphism of the STARD3 gene showed the most substantial association with the regression of CIMT in CAD patients.